[Growth hormone-releasing factor (GRF) stimulation test in the diagnosis of pituitary adenomas].
Krzyzagórska. E E; Kosowicz. J J
Key Findings
- GRF‑1‑29 was given to 33 patients with various pituitary adenomas to measure growth hormone release.
- Patients with acromegaly showed highly variable growth hormone responses; some increased, many did not.
- Prolactinoma patients often showed an early rise in growth hormone, while some with combined prolactinoma and acromegaly showed no response.
Practical Outcomes
- For biohackers or self‑experimenters, this research does not provide actionable dosing or performance benefits. It is primarily a diagnostic tool for doctors to assess pituitary function in tumor patients, so it has little relevance to everyday health optimization or longevity protocols.
Summary
This study looked at how a hormone-releasing peptide (GRF‑1‑29) can be used in a medical test to see how well the pituitary gland can release growth hormone in people with different types of pituitary tumors. The test showed a lot of variation in responses, and it was mainly useful for diagnosing tumors, not for improving health or performance.
Abstract
The studies aimed at evaluation of pituitary reserve of growth hormone following stimulation with GRF have been carried out in a group of 33 patients (11 women and 22 men, of age between 25 and 62 years) with pituitary tumors. The studied material included cases with pituitary adenoma characterized by excessive secretion of growth hormone (somatotropinoma), prolactin (prolactinoma) or alpha subunits of glycoprotein hormones (alphoma), and those with hormonally inactive adenoma. The GRF stimulation tests were carried out in hospitalized patients after overnight fast between 8.00 and 10.00 a.m. Blood samples for hormonal determinations were taken before the test, and after 15, 30, 60, 90 and 120 minutes following intravenous administration of 100 micrograms of GRF 1-29. Besides growth hormone, also the blood serum concentrations of other pituitary hormones were determined in the patients studied, both in the basal state and during the dynamic tests. In patients with acromegaly the results of the determinations of growth hormone following stimulation with GRF showed considerable individual variability. In 5 cases there was an increase in blood serum growth hormone concentration. No response to GRF was noted in the remaining 8 cases. In adenoma cases of prolactinoma type, growth hormone concentration began to rise already at the 15-th minute of the test in most cases. In three cases of prolactinoma associated with acromegaly no response to GRF was observed. The cases of alphoma-type adenoma were usually characterized by the secretion of pituitary hormones other than growth hormone.(ABSTRACT TRUNCATED AT 250 WORDS)
Study Information
pubmed
1988